The factor V HR2 haplotype and the risk of venous thrombosis: a meta-analysis.
OBJECTIVE
A complex haplotype of factor V gene (FV HR2) has been recently reported. FVHR2 possesses decreased co-factor activity to APC in the degradation of FVIIIa, and an increased ratio of the more procoagulant isoform FV1 compared to FV2. Contrasting results on whether the haplotype induces a significant risk of venous thromboembolism (VTE) have been reported.


METHODS
It has been surmised that FVHR2 enhances the risk of VTE carried by FV Leiden. We carried out a meta-analysis of the reported studies on the role of HR2 haplotype in inducing a risk of VTE and the influence of the polymorphism on the risk carried by patients with FV Leiden.


RESULTS
Eight studies were analyzed for the estimation of the risk of VTE. A total of 338 out of 2,696 cases (12.5%; range 7.8 to 18.5%) and 885 out of 7,710 controls (11.5%; range 8.1 to 12.1%) were HR2 positive. The odds ratio for VTE associated with HR2 haplotype was not statistically significant (OR 1.15; 95% C.I. 0.98-1.36). The OR for the association between FV Leiden and FV HR2 and the risk of VTE in cases and controls was largely heterogeneous as to OR and 95% C.I. and no statistical significant difference was observed.


CONCLUSIONS
The data from the present meta-analysis suggests that FVHR2 could be a very mild prothrombotic factor. The association of FV Leiden and HR2 haplotype seems not to increase significantly the risk of VTE carried by isolated heterozygosity for FV Leiden. However, well-designed clinical studies are needed to clarify this issue definitely.
Castaman
Giancarlo
G
Department of Hematology, San Bortolo Hospital, Vicenza, Italy. castaman@hemato.ven.it
Faioni
Elena M
EM
Tosetto
Alberto
A
Bernardi
Francesco
F
D005165:Factor V / Q000235:genetics*; D006239:Haplotypes / Q000235:genetics*; D006801:Humans; D017720:Molecular Epidemiology / Q000379:methods; D012307:Risk Factors; D020246:Venous Thrombosis / Q000453:epidemiology* / Q000235:genetics*
C095381:factor V Leiden; D005165:Factor V